Drugs / Navlimetostat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07800897 | Aug 2026 → Mar 2027 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07544628 | Apr → Nov 2026 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07579221 | Jul 2026 → Aug 2029 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06855771 | Sep 2025 → Dec 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07076121 | Oct 2025 → May 2029 expected | pancreatic ductal adenocarcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Navlimetostat | “Navlimetostat (BMS-986504)” NCT06855771 ↗ |
| Known as | BMS-986504 | “Navlimetostat (BMS-986504)” NCT06855771 ↗ |
| Action | Inhibit | “PRMT5 inhibitor” NCT07076121 ↗ |
| Route | Oral | “administered orally once daily (QD)” NCT07579221 ↗ |
| Target | PRMT5 | “PRMT5 inhibitor” NCT07076121 ↗ |